Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approv...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thyroid
Glavni autori: Ito, Yasuhiro, Onoda, Naoyoshi, Ito, Ken-ichi, Sugitani, Iwao, Takahashi, Shunji, Yamaguchi, Iku, Kabu, Koki, Tsukada, Katsuya
Format: Artigo
Jezik:Inglês
Izdano: Mary Ann Liebert, Inc. 2017
Teme:
Thyroid Cancer and Nodules
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://ncbi.nlm.nih.gov/pubmed/28635560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2016.0621
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items